Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model

Journal of Clinical Pharmacology

Volumn 37, Issue 10, 1997, Pages 881-892

  Hochhaus, Günther ^a,b,c   Möllmann, Helmut ^a,b   Derendorf, Hartmut ^a,b   Gonzalez Rothi, Ricardo J ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; HYDROCORTISONE; METHYLPREDNISOLONE; TRIAMCINOLONE ACETONIDE;

AEROSOL; ARTICLE; ASTHMA; BINDING AFFINITY; BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG VOLUME; RECEPTOR AFFINITY;

EID: 1842292795     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04262.x     Document Type: Article

References (36)

1. Barnes PJ, Pedersen S: Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993;148:S1-S26.
2. Barnes PJ: Inhaled glucocorticoids for asthma. N Engl J Med 1995;332:868-875.
3. Brogden RN, McTavish D: Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis [published errata appear in Drugs 1992 Dec;44(6): 1012 and 1993 Jan;45(1):130]. Drugs 1992;44:375-407.
4. Loennebo A, Grahnen A, Brundin RM, Ling-Andersson, Eckernaes SA: An assessment of the systemic effects of single and repeated doses of inhaled fluticasone proprionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 1996;49:459-463.
5. Grahnen A, Eckernas SA, Brundin RM, Ling Andersson A: An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994;38:521-525.
6. Dahlberg E, Thalen A, Brattsand R, Gustafsson J-A, Johansson U, Roemke K, Saartrok T: Correlation between chemical structure, Receptor binding, and biological activity of some novel, highly active, 16a,17a-acetal-substituted-glucocorticoids. Mol Pharmacol 1983;25:70-78.
7. Beato M, Rousseau GG, Feigelson P: Correlation between glucocorticoid binding to specific liver cytosol receptors and enzyme induction. Biochem Biophys Res Commun 1972;47:1464-1472.
8. Diamant A, Eshiel M, Ben-Or S: Interaction of cortisol with the neural retina of the chick embryo in culture. Cell Differentation 1975;4:101-112.
9. Baxter JD, Rousseau GG, Higgins SJ, Tomkins GM: Mechanism of glucocorticoid hormone action and of regulation of gene expression in cultured mammalian cells, in The Biochemistry of gene expression in Higher Organism., J.K. Pollack and J. Wilson Lee, Editors. 1973, Australian New Zealand Book: Sidney. 206-224.
10. Hochhaus G: Binding affinities of commercially available glucocorticoids to the glucocorticoid receptor of the human lung, in Institute of Pharmaceutical Chemistry. 1983, Westfaelische Wilhelms Universitaet: Muenster.
11. Druzgala P, Hochhaus G, Bodor N: Soft drugs 10: Blanching activity and receptor binding affinity of a new type of glucocorticoid: Loteprednol etabonate. J Steroid Biochem 1991;38: 149-154.
12. Byron P: Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986;75:433-438.
13. Gonda I: Drug administration directly into the respiratory tract: Modeling of the duration of effective drug levels. J Pharm Sci 1987;77:340-346.
14. Suarez S, Gonzalez-Rothi R, Hochhaus G: The effect of dose and release rate on pulmonary targeting of glucocorticoids using liposomes as a model dosage form. Pharm Res 1996;13(suppl): 157S.
15. Barnes PJ: Molecular mechanism of steroid action in asthma. J Allergy Clin Immunol 1996;97:159-168.
16. Melchor R, Biddiscome MF, Mak VHF, Short MD, Spiro SG: Lung disposition patterns of directly labeled salbutamol in normal subjects and in patients with reversible airflow obstructions. Thorax 1993;48:506-511.
17. Newman S, Steed K, Hooper G, Kallen A, Borgstrom L: Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler. Pharm Res 1995; 12:231-236.
18. Thorsson L, Edsbacker S, Conradson TB: Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994;7:1839-1844.
19. Hindle M, Newton D, Chrystyn H: Relative bioavailability of salbutamol to the lung following inhalation by a metered dose inhaler and a dry powder inhaler (abstract). Thorax 1993;48:433-434.
20. Hochhaus G, Gonzales-Rothi R, Lukyanov A, Derendorf H, Schreier H, Dalla Costa T: Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies. Pharm Res 1995; 12:134-137.
21. Gonzales-Rothi R, Suarez S, Hochhaus G, Schreier H, Lukyanov A, Derendorf H, Dalla Costa T: Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 1996; 13:1699-1703.
22. Hochhaus G, Möllmann H, Barth J: Glucocorticoids for intra-articular therapy: Pharmacodynamic characterization via receptor binding studies. Akt Rheumatol 1990;15:66-69.
23. Wuerthwein G, Rehder S, Rohdewald P: Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wiss 1992; 137:161-165.
24. Derendorf H, Moellmann H, Barth J, Moellmann C. Tunn S, Krieg M: Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol 1991;31:473-476.
25. Moellmann H, Rohdewald P, Barth J, Verho M, Derendorf H: Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. Biopharm Drug Dispos 1989;10:453.
26. Derendorf H, Moellmann H, Rohdewald P, Rehder J, Schmidt EW: Kinetics of methylprednisolone and its hemisuccinate ester. Clin Pharmacol Ther 1985;37:502-507.
27. Derendorf H, Moellmann H: Pharmacodynamics of methylprednisolone after single intravenous administration to healthy volunteers. Pharm Res 1991;8:263-268.
28. Duggan DE, Yeh KC, Matalia N, Ditzler CA, McMahon FG: Bioavailability of oral dexamethasone. Clin Pharmacol Ther 1975;18:205-209.
29. Peets E, Staub M, Synchowics S: Plasma protein binding of betamethasone-3H, dexamethasone-3H and cortisol-14C-a comparative study. Biochem Pharmacol 1969;18:1655-1663.
30. Derendorf H, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Erdmann M: Oral and pulmonary bioavailability of triamcinolone acetonide. J Clin Pharmacol 1995;35:302-305.
31. Chaplin MD, Rooks Wd, Swenson EW, Cooper WC, Nerenberg C. Chu NI: Flunisolide metabolism and dynamics of a metabolite. Clin Pharmncol Ther 1980;27:402-413.
32. Chaplin MD, Cooper WC, Segre EJ, Oren J, Jones RE, Nerenberg C: Correlation of flunisolide plasma levels to eosinopenic response in humans. J Allergy Clin Immunol 1980;65:445-453.
33. Ryrfeldt A, Andersson P, Edsbaecker S, Tonnesson M, Davies D, Pauwels R: Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982;63(suppl 122):86-95.
34. Mackie AE, Ventresca GP, Fuller RW, Bye A: Pharmacokinetics of intravenous fluticasone proprionate in healthy volunteers. Br J Clin Pharmacol 1996;41:539-542.
35. Harding SM: The human pharmacology of fluticasone propionate. Respir Med 1990;84:A25-A29.
36. Rohatagi S, Hochhaus G, Moellmann H. Barth J, Galia E, Erdmann M, Sourgens H, Derendorf H: Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide after Intravenous, Oral, and Inhaled Administration. J Clin Pharmacol 1995;35:1187-1193.